Skip to content
value.today

scPharmaceuticals Inc.

Total raised
$68 M
4 rounds on record
Latest round
$47 M
Dec 2016
First round on record
Mar 2014
Today
Acquired
Acquired by MannKind Corporation

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of scPharmaceuticals Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
scPharmaceuticals IncMannKind CorporationOct 2025Oct 2025$364 M—Annual report

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of scPharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$47 MNo. 4$10 to $50 million

scPharmaceuticals Inc.: Raise no. 4, Dec 2016

Investors in this round

11 investors had bought by the notice of Jan 6, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for scPharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$47 M of $47 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abraham Ceesay · Executive Officer
  • Pieter Muntendam · Executive Officer, Director
  • Troy Ignelzi · Executive Officer
  • Abhay Gandhi · Director
  • Dorothy Coleman · Director
  • Jack Khattar · Director
  • Jonathan Silverstein · Director
  • Kush Parmar · Director
  • Leonard Schaeffer · Director
  • Mette Agger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “From the Total Offering Amount approximately $41,000,000 was from new shares of Series B stock sold and $5,962,788 was from the conversion of debt into Series B stock.”

Signed by Troy Ignelzi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 6, 2017. Read the notice at the SEC.

equitySEC
Aug 2016$8 MNo. 3$2 to $10 million

scPharmaceuticals Inc.: Raise no. 3, Aug 2016

Investors in this round

15 investors had bought by the notice of Sep 6, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for scPharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abraham Ceesay · Executive Officer
  • Pieter Muntendam · Executive Officer, Director
  • Troy Ignelzi · Executive Officer
  • Dorothy Coleman · Director
  • Jack Khattar · Director
  • Kush Parmar · Director
  • Leonard Schaeffer · Director
  • Mette Agger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Troy Ignelzi, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 6, 2016. Read the notice at the SEC.

equitySEC
Jan 2016$4 MNo. 2$2 to $10 million

scPharmaceuticals Inc.: Raise no. 2, Jan 2016

Investors in this round

12 investors had bought by the notice of Feb 4, 2016: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for scPharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$171,800 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pieter Muntendam · Executive Officer, Director
  • Dorothy Kirstine Coleman · Director
  • Kush Parmar · Director
  • Leonard Kirstine Schaeffer · Director
  • Mette Kirstine Agger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds to be used for general working capital purposes, including the payment of compensation to certain of the directors and officers of the corporation listed as Related Persons in Item 3.”

Signed by Pieter Muntendam, President. Source: SEC Form D, newest notice filed Feb 4, 2016. Read the notice at the SEC.

debt, optionsSEC
Mar 2014$9 MNo. 1$2 to $10 million

scPharmaceuticals Inc.: Raise no. 1, Mar 2014

Investors in this round

9 investors had bought by the notice of Apr 7, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for scPharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $17 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pieter Muntendam · Executive Officer, Director
  • Kush Parmar · Director
  • Mette Kirstine Agger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Quillen, Secretary. Source: SEC Form D, newest notice filed Apr 7, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • scPharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).

    SEC Form D · Jan 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2017

That is all the official record says: scPharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in scPharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
5AM Co-Investors IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
5AM Partners IV, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
5AM Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Dorothy ColemanPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Invest A/s LundbeckfondPersonnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Leonard D. SchaefferPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Sun Pharmaceutical Industries, Inc.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by scPharmaceuticals Inc.
NameRoleNamed in
Abraham CeesayExecutive officerJan 2017
Pieter MuntendamExecutive officerJan 2017
Troy IgnelziExecutive officerJan 2017
Abhay GandhiDirectorJan 2017
Dorothy ColemanDirectorJan 2017
Jack KhattarDirectorJan 2017
Jonathan SilversteinDirectorJan 2017
Kush ParmarDirectorJan 2017
Leonard SchaefferDirectorJan 2017
Mette AggerDirectorJan 2017
Pieter MuntendamDirectorJan 2017
Dorothy Kirstine ColemanDirectorFeb 2016
Leonard Kirstine SchaefferDirectorFeb 2016
Mette Kirstine AggerDirectorFeb 2016

About

Company in Boston, United States.

Acquired (Oct 7, 2025). Acquired by MannKind Corporation.